Systematic review of ceftaroline fosamil in the management of patients with methicillin-resistant Staphylococcus aureus pneumonia

• Published in: European respiratory review Vol. 32; no. 170; p. 230117
• Main Authors: Torres, Antoní, Kuraieva, Alona, Stone, Gregory G, Cillóniz, Catia
• Format: Journal Article
• Language: English
• Published: England European Respiratory Society 31.12.2023
• Subjects: Adult; Anti-Bacterial Agents - adverse effects; Ceftaroline; Cephalosporins - adverse effects; Child; Community-Acquired Infections - diagnosis; Community-Acquired Infections - drug therapy; Humans; Linezolid; Methicillin-Resistant Staphylococcus aureus; Pneumonia, Ventilator-Associated - diagnosis; Pneumonia, Ventilator-Associated - drug therapy; Reviews; Vancomycin
• ISSN: 0905-9180; 1600-0617
• DOI: 10.1183/16000617.0117-2023

Methicillin-resistant (MRSA) is responsible for an array of problematic community- and healthcare-acquired infections, including pneumonia, and is frequently associated with severe disease and high mortality rates. Standard recommended treatments for empiric and targeted coverage of suspected MRSA in patients with community-acquired pneumonia (CAP) and hospital-acquired pneumonia (HAP), including ventilator-associated pneumonia (VAP), are vancomycin and linezolid. However, adverse events such as acute kidney injury and infection have been associated with these antibiotics. Ceftaroline fosamil is a β-lactam/extended-spectrum cephalosporin approved for the treatment of adults and children with CAP and complicated skin and soft tissue infections. Ceftaroline has activity against a range of common Gram-positive bacteria and is distinct among the β-lactams in retaining activity against MRSA. Due to the design of the pivotal randomised controlled trials of ceftaroline fosamil, outcomes in patients with MRSA CAP were not evaluated. However, various reports of real-world outcomes with ceftaroline fosamil for pneumonia caused by MRSA, including CAP and HAP/VAP, been published since its approval. A systematic literature review and qualitative analysis of relevant publications was undertaken to collate and summarise relevant published data on the efficacy and safety of ceftaroline fosamil in patients with MRSA pneumonia. While relatively few real-world outcomes studies are available, the available data suggest that ceftaroline fosamil is a possible alternative to linezolid and vancomycin for MRSA pneumonia. Specific scenarios in which ceftaroline fosamil might be considered include bacteraemia and complicating factors such as empyema.